The raised revenue and cash guidance, combined with the Eli Lilly deal and expanded xPloration commercial launch, signal accelerating top-line momentum and a strengthening balance sheet. Monitor the xPloration revenue trajectory and any additional partner milestones in coming quarters.
Price Chart
Executive Summary
OmniAb reported Q3 2026 revenue of $4.0M, up from $2.2M a year ago, and a net loss of $15.7M ($0.12 per share) versus a $16.5M loss in Q3 2025. The company raised its full-year 2026 revenue guidance to $35M-$39M (from $32M-$36M) and its year-end cash outlook to $53M-$57M, citing continued licensing execution and the expanded commercial launch of its xPloration platform.
Key Financial Metrics
Key Facts
- Q3 2026 total revenue of $4.0M, up 78% YoY from $2.2M.
- Net loss of $15.7M ($0.12 per share) improved from a $16.5M loss ($0.14 per share) in Q3 2025.
- Full-year 2026 revenue guidance raised to $35M-$39M from $32M-$36M.
- Year-end cash and cash equivalents guidance raised to $53M-$57M from $49M-$53M.
- Signed a global collaboration and license agreement with Eli Lilly for a new ion channel program, with up to $370M in milestone payments plus tiered royalties.
- Expanded commercial access to the xPloration platform, with expected 2026 xPloration revenue of $2M-$3M, projected to double in 2027 and again in 2028.
- Introduced OmniTides, a new peptide discovery offering.
- As of September 30, 2026, had 111 active partners and 433 active programs, including 34 clinical/commercial programs.
- Cash, cash equivalents and short-term investments of $64.2M as of September 30, 2026.
Financial Impact
Revenue guidance raised by $3M at the midpoint ($37M vs $34M previously), and cash outlook raised by $4M at the midpoint ($55M vs $51M). The Eli Lilly deal includes up to $370M in milestones plus royalties.
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| License and milestone revenue | $100.0K | -83.8% |
| Service revenue | $2.8M | +138.6% |
| xPloration revenue | $703.0K | +850.0% |
| Royalty revenue | $355.0K | -1.7% |
Risk Factors
- Revenue remains heavily dependent on partner milestones, which can be lumpy.
- Net loss persists; operating expenses are expected to remain in the $83M-$87M range.
- xPloration revenue projections are forward-looking and may not materialize as expected.
- Partner program clinical and regulatory timelines are outside OmniAb's control.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001846253-26-000049 |
| Document: oabi-20261030.htm | 0001846253-26-000049 |
| Document: 0001846253-26-000049-index-headers.html | 0001846253-26-000049 |
| Document: 0001846253-26-000049-index.html | 0001846253-26-000049 |
| Document: 0001846253-26-000049.txt | 0001846253-26-000049 |
| 8-K Data (Synthetic) | 0001846253-26-000049 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 30, 2026 2d ago | 8-K | $5.35 | awaiting T+20 | awaiting T+20 | $5.11 (−4.49%) |
Apr 7, 2026 29w ago | Insider Cluster | $1.51 $1.41 | ▼ −6.62% | ▼ −16.40% | $5.11 (+238.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers